Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.alkermes.com
Alkermes plc News Releases
Get the latest updates from Alkermes plc News Releases directly as they happen.
Follow now 37 followers
Latest posts
Last updated 17 days ago
Alkermes to Participate in Two Upcoming Investor Conferences
17 days ago
DUBLIN --(BUSINESS WIRE)--Nov. 25, 2025-- Alkermes plc (Nasdaq: ALKS) announced today that...
Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
24 days ago
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN...
Alkermes Response to Avadel Announcement
29 days ago
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) DIRECTLY...
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
about 1 month ago
– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate...
Alkermes to Participate in Two Upcoming Investor Conferences
about 1 month ago
DUBLIN , Nov. 6, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced...
FORM 8.1(a) & (b) (Opening Position Disclosure)
about 1 month ago
DUBLIN , Nov. 5, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS): IRISH...
Alkermes plc Reports Third Quarter 2025 Financial Results
about 2 months ago
— Third Quarter Revenues of $394.2 Million — — GAAP Net Income...
Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc
about 2 months ago
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN...
Alkermes to Report Third Quarter Financial Results on October 28, 2025
about 2 months ago
DUBLIN , Oct. 20, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will...
Alkermes Appoints Joshua Reed as Chief Financial Officer
3 months ago
DUBLIN , Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) is...
Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program
3 months ago
— Competitive Grant Program to Offer Individual Grants of Up to $100,000...
Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025
3 months ago
– First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically...